Question 1

What is NAD+, and is it a peptide?

Accepted Answer

NAD+ stands for nicotinamide adenine dinucleotide, and the first useful thing to say is that it is not a peptide. A 2025 review in Nutrients calls it a core coenzyme involved in cellular energy metabolism and redox homeostasis, which is the running balance between the reactions that give and take electrons inside a cell. A coenzyme is a small helper molecule that an enzyme needs before it can do its job. Peptides are short chains of amino acids, while NAD+ is built from two nucleotides, which makes it a different kind of molecule altogether. It is stocked beside peptides and searched for alongside them, and that is where the phrase nad peptide comes from. The label is wrong, and it matters mainly because the research sits in a different literature from the one most compounds on this site belong to.

Question 2

Has NAD+ been given to people in a trial?

Accepted Answer

Once, among the research behind this page, and the design matters more than the result. A proof-of-concept, 8-week, randomized, controlled, double-blind trial was conducted in 80 CFS patients assigned to receive either CoQ10 plus NADH supplementation or matching placebo twice daily. CFS is chronic fatigue syndrome, which the 2016 report describes as severe disabling fatigue with no known cause, no established diagnostic tests, and no universally effective treatment. NADH is a related molecule that cells shuttle back and forth with NAD+, and CoQ10 is coenzyme Q10, a separate compound sold for much the same reasons. Read the arms of that trial carefully, because everyone in the active group swallowed two compounds at once. Any change recorded in those 80 patients belongs to the pair rather than to NAD+ on its own.

Question 3

What did the one human trial measure?

Accepted Answer

Two readings moved and two did not. The CoQ10 plus NADH group showed a significant reduction in max HR during a cycle ergometer test at week 8 versus baseline (P = 0.022), which is a heart-rate figure taken on an exercise bike rather than anything the patients would notice. Perception of fatigue also showed a decrease through all follow-up visits in active group versus placebo (P = 0.03). However, pain and sleep did not improve in the active group, which is the qualification that rarely survives into promotional writing. The authors were plain about how much weight the result carries, writing that further additional larger controlled trials are needed to confirm these findings. One 8-week trial of two compounds in 80 patients is a reasonable place to begin an investigation rather than a settled answer.

Question 4

What does the animal work show for the brain?

Accepted Answer

Two mouse experiments point at the brain, and both used animals made ill on purpose. One team fed mice a drug called cuprizone, which strips the coating off nerves much as multiple sclerosis does. Six-week-old C57BL/6J mice were divided into three groups, and one group got a daily injection of NAD+. The mice in the cuprizone + NAD+ group received 250 mg/kg/day NAD+ intraperitoneally once a day, meaning straight into the belly. Those mice then moved better and did better on a maze, and the authors concluded that direct NAD+ supplementation improves the locomotor ability and spatial memory of cuprizone-intoxicated mice. Mood did not move, and the same paper found no significant effects on depressive and exploratory behavior. The other team used NR, short for nicotinamide riboside, in mice bred to carry the marks of Alzheimer's disease. After supplementation with NR for 8 weeks, the thinned-out gut mix of those mice came back toward normal. That is a shift in gut bacteria rather than a measurable change in anyone's memory.

Question 5

Where has NAD+ failed in animals?

Accepted Answer

Two rodent experiments came back empty, and they are the more useful half of the record. One 2025 team set off a short, sharp bout of confusion in mice, a state called delirium, and gave them NMN. NMN is short for nicotinamide mononucleotide, a direct precursor of Nicotinamide adenine dinucleotide. It did not rescue the delirium-like sickness behavior and metabolic dysfunction in mice, though a panel of immune markers did shift. A second team looked at waking up from anaesthesia in adult male and female C57BL/6 mice (n = 8-10/group). NADH (150 mg/kg, intraperitoneal) or vehicle (0.9% normal saline) were given at baseline or during anesthesia. This study demonstrates that NADH does not appear to hasten recovery from anesthesia, the authors wrote. The mice given NADH then moved less, not more: the NADH-treated group exhibited a significant decrease in open-field activity. A compound marketed for vitality making mice quieter is an observation worth sitting with.

Question 6

Does the word NAD+ on a label mean one thing?

Accepted Answer

Not reliably, and this is the most practical paragraph on the page. The experiments described above used four different molecules between them. The mouse brain work gave NAD+ itself. The anaesthesia work gave NADH, a common NAD+ precursor. The delirium work gave nicotinamide mononucleotide, usually shortened to NMN. The Alzheimer's work gave nicotinamide riboside, shortened to NR. A 2025 review pools the last two, noting that supplementation with NAD+ precursors also significantly elevates myocardial NAD+ levels to ameliorate heart failure. A precursor is raw material the body has to convert, which is not the same as the finished molecule arriving where you want it. The human trial used NADH and the mouse brain result used NAD+, so a headline about one of them is not a headline about the other.

Question 7

What is the heart research actually about?

Accepted Answer

A 2025 review in Nutrients is the most substantial NAD+ paper among the research behind this page, and it is a review of mechanism rather than a report of a trial. Its subject is heart failure, which it describes as the terminal stage in the development of many cardiovascular diseases. The authors write that NAD+ has been shown to potentially ameliorate heart failure through the regulation of mitochondrial function, mitochondria being the compartments inside a cell that make its energy. They are careful about what the paper amounts to, calling it a theoretical basis for understanding the central role of NAD+ in mitochondrial homeostasis. A theoretical basis is a reason to run a trial rather than a result from one. A 2022 Parkinson's paper has the same shape in its own title, calling NAD+ a potential disease-modifying agent targeting multiple pathways. No study among the research behind this page reports a heart outcome in a person given NAD+.

Question 8

How is NAD+ thought to work?

Accepted Answer

The short version is that NAD+ is something cells spend, and several enzymes cannot work without it. The 2025 Nutrients review reports that NAD+ acts to regulate mitochondrial biosynthesis and antioxidant defences through the activation of the deacetylase family, a set of enzymes that pull chemical tags off proteins and so change what those proteins do. The same review describes a second route, in which NAD+ works to increase mitochondrial autophagy to remove damaged mitochondria, which is the routine a cell uses to clear out worn parts. It adds that blocking the enzymes that break NAD+ down increases the tissue intracellular NAD+ content. Every step of that account was worked out in cells and in animals. Knowing how a molecule behaves inside a cell is a long way from knowing what swallowing more of it does to a person.

Question 9

What about NAD+ injections and drips?

Accepted Answer

The route people are sold is not the route that was studied. No study among the research behind this page gave NAD+ to a person by injection or by a drip into a vein. The injections on record went into mice, and they went into the abdominal cavity, which is not a route anybody uses in a clinic. In the multiple sclerosis work the mice in the cuprizone + NAD+ group received 250 mg/kg/day NAD+ intraperitoneally once a day. In the anaesthesia work it was a single injection of NADH before or during the procedure. One 2025 rodent paper does notice the consumer trade, observing that with rising over-the-counter use of NAD, understanding their impact on anesthetic recovery becomes essential. That sentence is about capsules rather than drips, and the distance between a mouse injection and a clinic infusion has not been measured.

Question 10

Does NAD+ do anything for weight?

Accepted Answer

No study among the research behind this page measured body weight, waist size or body fat in a person taking NAD+. That is the direct answer, and the nearest real finding sits some distance from it. The mouse experiments counted behaviour, gut bacteria, immune signals and recovery from anaesthesia. The one human trial counted heart rate on a bike, fatigue, pain and sleep, and perception of fatigue also showed a decrease through all follow-up visits in active group versus placebo. Fatigue is not fat. Two registered studies aim at metabolism without having reported, one called Nicotinamide Adenine Dinucleotide and Skeletal Muscle Metabolic Phenotype and another called Effects of NR Supplementation on Metabolic Flexibility in Zone 2 Training. How a muscle burns fuel and how much fat a body carries are different questions, and the second one has not been asked in this material.

Question 11

Does NAD+ give you energy?

Accepted Answer

Energy is the word NAD+ is sold on, and it is slippery because it means two different things. In biochemistry it means the reactions that shuttle electrons around inside a cell, and a 2025 review places NAD+ at the middle of those, calling it a core coenzyme involved in cellular energy metabolism and redox homeostasis. In ordinary speech it means how awake somebody feels when they get out of bed, which is a question about symptoms. Only the one human trial approached the second meaning, and it did so in patients with a fatigue condition rather than in healthy adults. Over 8 weeks fatigue perception fell against placebo in those 80 patients, while pain and sleep did not improve in the active group. Nothing in that design separates NAD+ from coenzyme Q10, and nothing in it describes a healthy person.

Question 12

What trials are registered?

Accepted Answer

Seven studies naming NAD+ or one of its building blocks sit on the public register among the research behind this page. The titles say more than the status lines do. One sets a named brand against the very thing it is meant to raise: Effectiveness of Qualia NAD+ Supplementation on Intracellular NAD Levels. Two are marked completed, one on NR and exercise, the other on how the body answers a nutritional supplement. A third, filed as a phase 4 study of nutrients in older adults, is marked completed as well. A fourth, on vitamins for mood and impulse control, carries the status unknown, which on that register usually means nobody came back to update it. Only one reads as open: Effects of NR Supplementation on Metabolic Flexibility in Zone 2 Training is marked recruiting. A registration is an intention filed in public rather than a finding, and completed means the investigation stopped rather than that anybody can read it.

Question 13

What is documented about downsides?

Accepted Answer

The documented record is thin and almost all of it is rodent. In the anaesthesia experiment the NADH-treated group exhibited a significant decrease in open-field activity relative to vehicle-treated, and there was a depression in open-field activity and no change in Y-maze performance with NADH supplementation. Less movement in a mouse is an observation rather than a side effect in a person, though it runs the opposite way to what buyers expect. The same authors press the point about surgery, arguing for understanding the potential influence of administering NAD+ on anesthetic sensitivity and recovery. The human exposure on record runs to 8 weeks in 80 patients who were taking two compounds at once, and that is the whole of it among the research behind this page. What happens over years has not been measured in any of that material. Which organs have actually been examined, in which animals and over what durations, is taken question by question at the NAD+ safety page.

Question 14

Is NAD+ approved, and what does that mean for a bottle?

Accepted Answer

No approved indication for NAD+ appears among the research behind this page, and nothing in that material sets out a label, a schedule or an official purity standard. What follows from an absent label is specific rather than vague. There is no approved amount to measure a capsule against, no approved route, and no official reference a laboratory report could be checked against. The one consumer form these papers name is the counter one, in the 2025 observation about rising over-the-counter use of NAD. One registered study tests a named brand, Effectiveness of Qualia NAD+ Supplementation on Intracellular NAD Levels, which is as close as this material comes to examining something a person can actually buy. A container that does not state which of the four molecules it holds was not what any of these experiments used.

NAD+